These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 8492087)
21. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. O'Connor PM; Jackman J; Jondle D; Bhatia K; Magrath I; Kohn KW Cancer Res; 1993 Oct; 53(20):4776-80. PubMed ID: 8402660 [TBL] [Abstract][Full Text] [Related]
22. Morphologic conversion of a neuroblastoma-derived cell line by E6-mediated p53 degradation. Gaitonde SV; Qi W; Falsey RR; Sidell N; Martinez JD Cell Growth Differ; 2001 Jan; 12(1):19-27. PubMed ID: 11205742 [TBL] [Abstract][Full Text] [Related]
23. Sensitivity of p53 lysine mutants to ubiquitin-directed degradation targeted by human papillomavirus E6. Crook T; Ludwig RL; Marston NJ; Willkomm D; Vousden KH Virology; 1996 Mar; 217(1):285-92. PubMed ID: 8599213 [TBL] [Abstract][Full Text] [Related]
24. Immunoexpression of mutant p53 and human papillomavirus related E6 oncoprotein in anal malignancies. Gupta S; Sharma BK Indian J Exp Biol; 1998 Sep; 36(9):875-8. PubMed ID: 9854426 [TBL] [Abstract][Full Text] [Related]
25. Hemi- or homozygosity: a requirement for some but not other p53 mutant proteins to accumulate and exert a pathogenetic effect. Bhatia K; Goldschmidts W; Gutierrez M; Gaidano G; Dalla-Favera R; Magrath I FASEB J; 1993 Jul; 7(10):951-6. PubMed ID: 8344493 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation. Sherman L; Jackman A; Itzhaki H; Stöppler MC; Koval D; Schlegel R Virology; 1997 Oct; 237(2):296-306. PubMed ID: 9356341 [TBL] [Abstract][Full Text] [Related]
27. HPV-16 E6 oncoprotein induces mutations via p53-dependent and -independent pathways. Kim HJ; Guo W; Park NH Oncol Rep; 2000; 7(4):707-12. PubMed ID: 10854530 [TBL] [Abstract][Full Text] [Related]
28. Specific HIV protease inhibitors inhibit the ability of HPV16 E6 to degrade p53 and selectively kill E6-dependent cervical carcinoma cells in vitro. Hampson L; Kitchener HC; Hampson IN Antivir Ther; 2006; 11(6):813-25. PubMed ID: 17310826 [TBL] [Abstract][Full Text] [Related]
29. HPV-16E6 can induce multiple site phosphorylation of p53. Zhang G; Sun L; Li Z; Si L; Song T; Huang C; Zhang W Oncol Rep; 2009 Feb; 21(2):371-7. PubMed ID: 19148510 [TBL] [Abstract][Full Text] [Related]
30. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Sun SY; Yue P; Wu GS; El-Deiry WS; Shroot B; Hong WK; Lotan R Cancer Res; 1999 Jun; 59(12):2829-33. PubMed ID: 10383141 [TBL] [Abstract][Full Text] [Related]
31. p53-Dependent and -independent transactivation by the E6 protein of human papillomavirus type 16. Akutsu N; Shirasawa H; Asano T; Isono K; Simizu B J Gen Virol; 1996 Mar; 77 ( Pt 3)():459-63. PubMed ID: 8601782 [TBL] [Abstract][Full Text] [Related]
32. Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Pim D; Massimi P; Banks L Oncogene; 1997 Jul; 15(3):257-64. PubMed ID: 9233760 [TBL] [Abstract][Full Text] [Related]
33. An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication. Smardova J; Grochova D; Fabian P; Moulis M; Smarda J; Falkova I; Ravcukova B; Vankova J; Vasova I Oncol Rep; 2008 Oct; 20(4):773-8. PubMed ID: 18813817 [TBL] [Abstract][Full Text] [Related]
34. The role of TP53 in Cervical carcinogenesis. Tommasino M; Accardi R; Caldeira S; Dong W; Malanchi I; Smet A; Zehbe I Hum Mutat; 2003 Mar; 21(3):307-12. PubMed ID: 12619117 [TBL] [Abstract][Full Text] [Related]
35. Comparative analysis of 19 genital human papillomavirus types with regard to p53 degradation, immortalization, phylogeny, and epidemiologic risk classification. Hiller T; Poppelreuther S; Stubenrauch F; Iftner T Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1262-7. PubMed ID: 16835321 [TBL] [Abstract][Full Text] [Related]
36. Dispensability of p53 degradation for tumorigenicity and decreased serum requirement of human papillomavirus type 16 E6. Inoue T; Oka K; Yong-Il H; Vousden KH; Kyo S; Jing P; Hakura A; Yutsudo M Mol Carcinog; 1998 Mar; 21(3):215-22. PubMed ID: 9537653 [TBL] [Abstract][Full Text] [Related]
37. HPV-16 E7 or adenovirus E1A can overcome the growth arrest of cells immortalized with a temperature-sensitive p53. Vousden KH; Vojtesek B; Fisher C; Lane D Oncogene; 1993 Jun; 8(6):1697-702. PubMed ID: 8389035 [TBL] [Abstract][Full Text] [Related]
38. A plant lignan, 3'-O-methyl-nordihydroguaiaretic acid, suppresses papillomavirus E6 protein function, stabilizes p53 protein, and induces apoptosis in cervical tumor cells. Allen KL; Tschantz DR; Awad KS; Lynch WP; DeLucia AL Mol Carcinog; 2007 Jul; 46(7):564-75. PubMed ID: 17393435 [TBL] [Abstract][Full Text] [Related]
39. HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Pim D; Banks L Oncogene; 1999 Dec; 18(52):7403-8. PubMed ID: 10602499 [TBL] [Abstract][Full Text] [Related]
40. The properties of p53 proteins selected for the loss of suppression of transformation. Olson DC; Levine AJ Cell Growth Differ; 1994 Jan; 5(1):61-71. PubMed ID: 8123594 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]